Lipid profile after switching from TDF (tenofovir disoproxil)-containing to TAF (tenofovir alafenamide)-containing regimen in virologically suppressed people living with HIV

Background. Tenofovir disoproxil fumarate (TDF) or its prodrug tenofovir alafenamide fumarate (TAF) are currently being recommended in treatment of HIV infection. Distinct pharmacological properties of these two forms of a this drug make TAF treatment less nephrotoxic and lead to better impact on b...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Michał Łomiak, Zofia Gajek, Jan Stępnicki, Agnieszka Lembas, Tomasz Mikuła, Alicja Wiercińska-Drapało
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Poznan University of Medical Sciences 2023-09-01
Edice:	Journal of Medical Science
Témata:	antiretroviral therapy tenofovir disoproxil fumarate tenofovir alafenamide lipids cholesterol low-density lipoproteins
On-line přístup:	https://jms.ump.edu.pl/index.php/JMS/article/view/808
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!